NEW YORK and MELBOURNE, Australia, April 10, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Phase 3 trial of its allogeneic mesenchymal precursor cell (MPC ...
Tenax Therapeutics (TENX) is in a very good position as far as its drug development plan goes for its drug levosimendan. That's because it is already in the process of running the ongoing phase 3 ...
Novartis’ phase 3 trial of serelaxin in acute heart failure has missed its primary endpoint. The Swiss pharma saw the 6,600-patient trial as a way to bounce back from FDA’s 2014 rejection, but instead ...
Alector, Inc. is a pre-revenue biotech reset after Latozinemab’s Phase 3 failure, now trading at a deep discount. Nivisnebart, targeting Alzheimer’s, is ALEC’s next major catalyst; interim Phase 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback